Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA,
Nephron. 2019;143(3):193-196. doi: 10.1159/000500550. Epub 2019 May 16.
Delayed allograft function (DGF) is defined as dialysis treatment in the kidney transplant recipient in the first week following transplantation. With the demand for kidney transplants growing and the supply limited, as well as implementation of a national allocation scheme for deceased donor kidneys, rates of DGF remain high, on average, 30% for recipients of deceased donor kidneys. DGF is associated with inferior allograft outcomes, and there are no FDA-approved therapies to mitigate this disorder. There is renewed interest in this therapeutic arena, and there are several recent clinical trials that have considered interventions within the recipient to reduce injury. A critical issue is that of trial design and end points as well as translating from acute kidney injury (AKI) trials in cardiac bypass to the more complicated kidney transplant scenario. DGF is a significant clinical outcome after kidney transplantation without known approved therapy beyond clinical support. This mini-review highlights our presentation at the 24th International Conference on Advances in Critical Care Nephrology and UAB/UCSD O'Brien Center AKI Pre-Meeting.
延迟移植物功能（DGF）定义为移植后第一周内接受肾移植的患者进行透析治疗。由于对肾移植的需求不断增长而供体有限，以及实施了全国分配方案用于已故供体的肾脏，DGF 的发生率仍然很高，平均而言，已故供体肾脏的接受者为 30%。DGF 与移植物预后不良有关，目前还没有获得 FDA 批准的疗法来减轻这种疾病。在这个治疗领域重新引起了人们的兴趣，最近有几项临床试验考虑了在受者体内进行干预以减少损伤。一个关键问题是试验设计和终点，以及将心脏搭桥术的急性肾损伤（AKI）试验转化为更复杂的肾移植情况。DGF 是肾移植后的一个重要临床结果，除了临床支持外，没有已知的经批准的治疗方法。本篇迷你综述强调了我们在第 24 届危重病肾脏病学国际会议和 UAB/UCSD O'Brien 中心 AKI 会前会议上的演讲。
